180 Life Sciences Corp. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATNF Nasdaq 2836 180lifesciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 180 Life Sciences Corp.

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules - Dec 27th, 2024 2:00 pm
180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules - Dec 12th, 2024 1:00 pm
180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors - Dec 4th, 2024 1:00 pm
180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration - Oct 31st, 2024 12:00 pm
180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors - Oct 29th, 2024 12:00 pm
Elray Resources Announces Strategic Sale of Crypto iGaming Technology - Oct 25th, 2024 1:00 pm
180 Life Sciences' Brave Decision To Switch to the iGaming Industry - Oct 17th, 2024 2:52 pm
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform - Oct 16th, 2024 12:00 pm
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector - Oct 9th, 2024 12:30 pm
180 Life Sciences Corp. - Corporate Updates - Oct 3rd, 2024 12:30 pm
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer - Sep 12th, 2024 8:15 pm
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake - Jul 30th, 2024 12:00 pm
180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Jul 23rd, 2024 12:00 pm
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Jul 2nd, 2024 12:30 pm
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement - Mar 14th, 2024 12:30 pm
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan - Feb 26th, 2024 12:00 pm